Viewing data from:

GEMMILY

ANDA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE | A213317 | XIROMED PHARMA ESPANA SL

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: TAYTULLA(TE code: AB)

Medicare Part D Spending

CMS annual spending data for Gemmily (2023)

Total Spending

$12K

Total Claims

Beneficiaries

Avg Cost/Unit

$3.10

Spending Trend

$15K(2021)→$19K(2022)→$12K(2023)

YoY Change:-31.2%

5yr CAGR:-15.3%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jan 7, 2021	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 0.02MG;1MG

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Nov 9, 2020

No patent or exclusivity listings for this strength.